Role of bone marrow-derived mesenchymal stem cells in treating colitis through Fas/FasL-mediated immune regulation

• Published in: Xi bao yu fen zi mian yi xue za zhi Vol. 29; no. 10; p. 1028
• Main Authors: Yu, Yang, Shao, Bingyi, Shuai, Yi, Shang, Fengqing, Wang, Xi, Zhou, Zhifei, Liao, Li, Jin, Yan, Yang, Deqin
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2013
• Subjects: Animals; Apoptosis; Cell Movement; Colitis - immunology; Colitis - therapy; Fas Ligand Protein - physiology; fas Receptor - physiology; Female; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells - physiology; Mice; Mice, Inbred C57BL; T-Lymphocytes - immunology
• ISSN: 1007-8738

To investigate the difference in the therapeutic effects of bone marrow-derived mesenchymal stem cells (BMSCs) of mice from ovariectomy (OVX) group and sham group in treating colitis, and then further study the differences of Fas/FasL expression and downstream T cell migration and apoptosis between the two groups. The osteoporosis animal models were set up by ovariectomy in C57BL6 mice. Meanwhile, 3% dextran sulfate sodium (DSS) was administered for inducing colitis. We compared the therapeutic effects of BMSCs from OVX and sham groups in treating colitis, in addition, detected the expression of Fas/FasL in BMSCsby means of RT-PCR and Western blotting. The ability of BMSCs from the two groups of inducing T cell migaration and apoptosis was also detected. Compared with the sham group, BMSCs from OVX mice expressed a lower level of Fas/FasL and displayed a decreased ability of inducing T cell migration and apoptosis, thus leading to an inferior therapeutic effect in treating colitis in animal models. Fas/FasL e